MNPR - Monopar Therapeutics Inc.
After hours:
| Previous close | 0.9200 |
| Open | 0.9000 |
| Bid | 0.9400 x 900 |
| Ask | 0.9400 x 1200 |
| Day's range | 0.9000 - 0.9800 |
| 52-week range | 0.8110 - 4.8800 |
| Volume | |
| Avg. volume | 282,284 |
| Market cap | 12.483M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Zacks
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Simply Wall St.
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
- Simply Wall St.
Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Zacks
Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
